Australia markets open in 5 hours 54 minutes

Phreesia, Inc. (PHR)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
25.40-0.28 (-1.09%)
As of 02:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close25.68
Bid25.49 x 1300
Ask25.54 x 1000
Day's range25.10 - 25.78
52-week range13.19 - 76.10
Avg. volume485,626
Market cap1.334B
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-3.08
Earnings date06 Dec 2022 - 12 Dec 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.92
  • Zacks

    Can Phreesia (PHR) Climb 26% to Reach the Level Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Business Wire

    Phreesia Names Alexandra Beneville Vice President of Life Sciences Content Strategy

    WILMINGTON, Del., September 22, 2022--Phreesia, a leader in patient intake, outreach and activation, has named Alexandra Beneville as Vice President of Life Sciences Content Strategy. Beneville officially joined Phreesia on Aug. 1, 2022, from Phosphorus, a direct-to-consumer genomic testing company, where she had served as Vice President of Marketing since December 2021.

  • Business Wire

    Phreesia’s Zeeshan Butt Named to NQF’s MAP Clinician Workgroup

    WILMINGTON, Del., September 16, 2022--Phreesia is proud to announce that Zeeshan Butt, PhD, a Director of Clinical Content, has been selected to serve a three-year term as a member of the National Quality Forum (NQF)’s Measure Applications Partnership (MAP) 2022-2023 Clinician Workgroup.